Congratulations to the entire team on their $40M investment round, announced today! And it’s on the heels of their announcement of the industry’s first-ever AI-discovered drug candidate.
By focusing on the information-systems of our biology, from genetic disorders to genetic therapies, Deep Genomics can train their machine learning on the code — finding errant code and fixing it with digital RNA therapies — rather than the analog complexity and hit-and-miss methodology of small molecule drug design. As RNA therapy delivery chemistries unlock new organs and tissues, their approach can address a growing number of serious medical disorders.
Today’s news from FierceBiotech and Endpoints News:
“Therapeutically re-engineering the human genome is the final frontier,” said Brendan Frey, founder and CEO of Deep Genomics. “We have found that the more we explore the universe of genetic therapies using AI, the more we discover dark regions that can be illuminated only with the development of new technology.”
“This approach, the company explained, results in remarkable clarity and speed, as 70% of research projects have led to therapeutic leads, and programs have been taken from target discovery to drug candidate in less than a year.”
“For over twenty years, our team at Future Ventures has backed visionary companies seeking to change the world for the better,” said Steve Jurvetson, co-founder of Future Ventures and board member of Tesla and SpaceX. “Deep Genomics has pioneered a better way to systematically discover new therapies with a much higher success rate than traditional pharma methods. My partner Maryanna Saenko and I are excited to be joining them on a journey to modernize drug development by using AI to design and de-risk drug development programs up front, instead of relying on trial-and-error experiments that are fraught with time delays and high cost.”
Maryanna serves on the board of directors of Deep Genomics, and Future Ventures led today’s financing.
And last year from FierceBiotech and BusinessWire:
“Deep Genomics reveals the first-ever AI-discovered drug candidate. ‘We have built a system that within two hours can scan over 200,000 pathogenic patient mutations and automatically identify potential drug targets,’ Frey said.”
“Researchers have struggled for two decades, without success, to understand the mechanism of this genetic mutation that causes Wilson disease,” said Frederick K. Askari, M.D., Ph.D., associate professor and director of the Wilson disease program at the University of Michigan. “The clarity that this artificial intelligence platform has brought to the scientific community is astounding and the potential of a therapy that could operate at the genomic level to correct the disease process is exciting. Patients can now have hope that a therapy may be developed that will recapitulate normal gene function and make their problems go away.”
Hiring in Toronto: DeepGenomics.com
Leave a Reply